Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor)
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jan. 6, 2021-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D ., Executive Chairman of the Board of Directors, will participate in the 39 th Annual J.P.
Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves Computer-based molecular dynamics
Dr. Benedetti Brings More Than 20 Years in Oncology Clinical Development and Global Large Pharma Experience CULVER CITY, Calif., December 30, 2020 – ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti, M.D.
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious disease programs for HIV and COVID-19
BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The second-generation human
N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- ImmunityBio, a privately-held immunotherapy company, today announced the publication in
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Nov. 18, 2020-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32 nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020 .
First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design CULVER CITY, Calif. & EL SEGUNDO, Calif. --(BUSINESS WIRE)--Nov.
Study shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2 infection, demonstrating that the S and N antigens from the vaccine are recognized by SARS-COV-2 reactive human T cells Study results suggest